|
|
Article: Promising Results Observed In Topical Alprostadil Cream Trial.(Brief Article)
- Article from:
- Women's Health Weekly
- Article date:
- November 15, 2001
CopyrightCOPYRIGHT 2001 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2001 NOV 15 - (NewsRx.com & NewsRx.net) -- NexMed, Inc. announced that Phase I clinical trial data from the use of Femprox (active ingredient alprostadil) in women with female sexual arousal disorder (FSAD) were encouraging.
The study was conducted at the UMDNJ Robert Wood Johnson Medical School. Femprox is NexMed's proprietary cream for the treatment of FSAD and incorporates alprostadil with the patented NexACT transdermal penetration enhancement technology. In May 2001, NexMed completed its Phase I clinical program for Femprox, and initiated a Phase II study, which is enrolling up to 110 patients at up to 12 research sites throughout the U.S.
The ...